Your browser doesn't support javascript.
loading
Evaluation of a Digital Health Tool for Titration of Basal Insulin in People With Type 2 Diabetes: Rationale and Design of a Randomized Controlled Trial.
Hermanns, Norbert; Ehrmann, Dominic; Finke-Gröne, Katharina; Roos, Timm; Freckmann, Guido; Kulzer, Bernhard.
Affiliation
  • Hermanns N; Research Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany.
  • Ehrmann D; Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.
  • Finke-Gröne K; Diabetes Center Mergentheim, Bad Mergentheim, Germany.
  • Roos T; Research Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany.
  • Freckmann G; Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.
  • Kulzer B; Research Institute Diabetes Academy Mergentheim, Bad Mergentheim, Germany.
J Diabetes Sci Technol ; : 19322968221148756, 2023 Jan 05.
Article in En | MEDLINE | ID: mdl-36602040
ABSTRACT

BACKGROUND:

Optimal insulin titration is essential in helping people with type 2 diabetes mellitus (T2DM) to achieve adequate glycemic control. Barriers of people with diabetes to implementation of titration include lack of self-efficiency and self-management skills, increased diabetes-related distress, low treatment satisfaction, poor well-being, as well as concerns about hypoglycemia and insulin overdose. My Dose Coach is a digital health tool for optimizing titration of basal insulin that combines a smartphone app for patients with T2DM and a Web portal for health care professionals. METHODS/

DESIGN:

This is a prospective, open-label, multicenter, randomized controlled parallel study conducted in approximately 50 centers in Germany that are specialized in the treatment of diabetes. Patients in the intervention group will use the titration app and will be registered on the Web portal by their treating physician. Control group patients will continue their current basal insulin titration without using the app. The primary outcome is the mean change in HbA1c levels at the 12-week follow-up. The secondary outcome measures include patient-reported outcomes such as diabetes-related distress, self-management, empowerment, self-efficacy, treatment satisfaction, and psychological well-being as well as fasting blood glucose values.

CONCLUSION:

This digital health tool has been previously implemented in several independent pilot studies. The findings from this multicenter randomized controlled trial can provide further evidence supporting the effectiveness of this tool in patients with T2DM and serve as a basis for its clinical integration. TRIAL REGISTRATION German Register for Clinical Studies-DRKS-ID DRKS00024861.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Diabetes Sci Technol Journal subject: ENDOCRINOLOGIA Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: J Diabetes Sci Technol Journal subject: ENDOCRINOLOGIA Year: 2023 Type: Article Affiliation country: Germany